BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a strong sell rating to a sell rating in a report issued on Friday morning, BidAskClub reports.

A number of other research firms have also weighed in on CSII. Needham & Company LLC raised Cardiovascular Systems from a hold rating to a buy rating and set a $44.00 target price on the stock in a report on Thursday, June 11th. They noted that the move was a valuation call. Aegis lifted their price objective on shares of Cardiovascular Systems from $45.00 to $47.00 and gave the stock a buy rating in a research report on Wednesday, August 12th. Barclays started coverage on shares of Cardiovascular Systems in a report on Friday, July 17th. They issued an overweight rating and a $45.00 price objective on the stock. Northland Securities began coverage on shares of Cardiovascular Systems in a research note on Wednesday, July 22nd. They set an outperform rating and a $40.00 target price for the company. Finally, SVB Leerink lifted their target price on shares of Cardiovascular Systems from $40.00 to $45.00 and gave the stock an outperform rating in a report on Wednesday, August 5th. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $46.22.

Cardiovascular Systems stock opened at $34.09 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.46 and a quick ratio of 5.84. The company’s 50-day moving average is $31.71 and its 200-day moving average is $35.18. The firm has a market capitalization of $1.35 billion, a PE ratio of -43.70 and a beta of 1.33. Cardiovascular Systems has a fifty-two week low of $26.00 and a fifty-two week high of $55.22.

Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings results on Tuesday, August 4th. The medical device company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. The business had revenue of $42.55 million during the quarter, compared to analysts’ expectations of $38.51 million. Cardiovascular Systems had a negative return on equity of 15.62% and a negative net margin of 11.51%. As a group, analysts expect that Cardiovascular Systems will post -0.44 EPS for the current year.

In other news, insider Sandra Sedo sold 2,914 shares of Cardiovascular Systems stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $31.94, for a total value of $93,073.16. Following the completion of the sale, the insider now directly owns 67,467 shares in the company, valued at $2,154,895.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Martha Goldberg Aronson purchased 3,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was bought at an average price of $32.22 per share, with a total value of $96,660.00. Following the completion of the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $193,320. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,200 shares of company stock valued at $135,200 and sold 8,731 shares valued at $279,300. Insiders own 3.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CSII. Mutual of America Capital Management LLC lifted its position in shares of Cardiovascular Systems by 24.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 1,547 shares of the medical device company’s stock valued at $54,000 after acquiring an additional 306 shares during the period. Point72 Hong Kong Ltd acquired a new position in Cardiovascular Systems in the second quarter valued at about $56,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Cardiovascular Systems by 23.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,899 shares of the medical device company’s stock valued at $102,000 after purchasing an additional 557 shares in the last quarter. Advisor Group Holdings Inc. bought a new stake in Cardiovascular Systems during the first quarter worth about $111,000. Finally, UBS Group AG grew its stake in Cardiovascular Systems by 183.2% during the first quarter. UBS Group AG now owns 3,742 shares of the medical device company’s stock worth $132,000 after buying an additional 8,238 shares in the last quarter. Hedge funds and other institutional investors own 90.61% of the company’s stock.

About Cardiovascular Systems

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

See Also: What is intrinsic value?

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.